Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dryvax smallpox vaccine
ACAM3000 MVA Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112 |
| B | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with no Challenge |
| C | PLACEBO_COMPARATOR | Placebo |
| D | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112 |
| E | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112 |
| Name | Type | Description |
|---|---|---|
| ACAM3000 MVA Vaccine | BIOLOGICAL | Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days |
Inclusion Criteria: Subjects must meet the following to be eligible for the study: * adult males or females who provided informed consent for the study. * adults 18 and 31 years (inclusive). * good general health, * female subjects must not be pregnant or lactating and be on appropriate contracept...
ACAM3000 MVA Vaccine is an investigational vaccine developed by Sanofi for protection against smallpox. It is based on Modified Vaccinia Ankara (MVA), a weakened strain of vaccinia virus. The vaccine is designed to stimulate an immune response without using replication-competent vaccinia virus. It has been studied in a Phase 1 clinical trial in healthy adults.
ACAM3000 MVA Vaccine is being developed for the prevention of smallpox, a serious infectious disease caused by the variola virus. Smallpox has been eradicated globally, but the vaccine is intended for use in populations that may be at risk, including those who cannot safely receive traditional smallpox vaccines. It is not yet approved for any indication.
ACAM3000 MVA Vaccine is developed by Sanofi, a global pharmaceutical company. Sanofi trades on the New York Stock Exchange under the ticker symbol SNY. The vaccine is part of Sanofi's infectious disease portfolio.
ACAM3000 MVA Vaccine is in Phase 1 clinical development. It has completed one Phase 1 trial in the United States. The vaccine is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
ACAM3000 MVA Vaccine has been evaluated in one completed Phase 1 clinical trial, NCT00079820, titled "Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults." The trial enrolled 110 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.